Kairos Pharma Wins Clinical Trials Award for Prostate Cancer Treatment Innovation
TL;DR
Kairos Pharma's award-winning ENV-105 offers investors a competitive edge by targeting treatment resistance in advanced prostate cancer with promising Phase 2 trial results.
Kairos Pharma's ENV-105 is a CD105-targeting monoclonal antibody that works by reversing drug resistance to restore effectiveness of standard cancer therapies in clinical trials.
Kairos Pharma's ENV-105 development addresses significant unmet medical needs in prostate cancer, potentially improving treatment outcomes and quality of life for patients worldwide.
Kairos Pharma won a 2025 Clinical Trials Arena award for ENV-105, a first-in-class antibody targeting CD105 to overcome cancer treatment resistance in ongoing trials.
Found this article helpful?
Share it with your network and spread the knowledge!
Kairos Pharma Ltd. has been named a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer. The recognition acknowledges the company's advancement of ENV-105, a first-in-class CD105-targeting monoclonal antibody being developed to address treatment resistance in metastatic castration-resistant prostate cancer. This award follows positive interim safety and efficacy results from a Phase 2 randomized clinical trial evaluating ENV-105 in combination with apalutamide. This development is significant because metastatic castration-resistant prostate cancer represents a challenging stage of the disease where patients have limited treatment options after developing resistance to standard therapies.
ENV-105 targets CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information, elevation of CD105 in response to standard therapy results in resistance and disease relapse. The antibody aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, both aimed at addressing significant unmet medical needs. The company's approach utilizes structural biology to overcome drug resistance and immune suppression in cancer, positioning their work at the forefront of oncology therapeutics.
The full press release announcing the award can be viewed at https://ibn.fm/jWi2c. The Clinical Trials Arena Excellence Awards recognize outstanding contributions to clinical research and development across various therapeutic areas. This recognition comes at a time when advanced prostate cancer treatments face significant challenges with drug resistance. The development of therapies like ENV-105 that specifically target resistance mechanisms represents an important direction in oncology research. The interim results from the Phase 2 trial suggest potential for this approach to improve outcomes for patients who have exhausted standard treatment options.
As clinical trials continue, the medical community will be watching for further data on ENV-105's safety and efficacy profile. The combination approach being tested with apalutamide represents a strategic attempt to overcome resistance mechanisms that have limited the effectiveness of existing prostate cancer treatments. The award recognition underscores the importance of innovative approaches to addressing treatment resistance in advanced cancers. The latest news and updates relating to Kairos Pharma are available in the company's newsroom at https://ibn.fm/KAPA.
Curated from InvestorBrandNetwork (IBN)
